Boehringer signs deal to develop cystic fibrosis gene therapy

09-08-2018

Boehringer signs deal to develop cystic fibrosis gene therapy

filograph / iStockphoto.com

Boehringer Ingelheim has teamed up with academic institutions and research companies in the UK to develop a long-term gene therapy for cystic fibrosis, according to a statement released on Monday, August 6.


Boehringer, Imperial Innovations, Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, gene therapy, research and development, commercialisation

LSIPR